Overview

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Status:
Completed
Trial end date:
2015-05-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
Phase:
Phase 1
Details
Lead Sponsor:
Shire